Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - simvastatin, quantity: 20 mg; ezetimibe, quantity: 10 mg - tablet - excipient ingredients: citric acid monohydrate; propyl gallate; hypromellose; lactose monohydrate; butylated hydroxyanisole; ferric oxide; ascorbic acid; magnesium stearate; croscarmellose sodium; microcrystalline cellulose - adults (greater than or equal to 18 years),prevention of cardiovascular disease,simtorsi is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,simtorsi is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),simtorsi is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),simtorsi is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),simtorsi is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - ezetimibe, quantity: 10 mg; simvastatin, quantity: 10 mg - tablet - excipient ingredients: ferric oxide; hypromellose; lactose monohydrate; ascorbic acid; croscarmellose sodium; butylated hydroxyanisole; microcrystalline cellulose; magnesium stearate; citric acid monohydrate; propyl gallate - adults (greater than or equal to 18 years),prevention of cardiovascular disease,apo-ezetimine/simvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of simvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties - clinical trials),primary hypercholesterolaemia,apo-ezetimine/simvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),apo-ezetimine/simvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),apo-ezetimine/simvastatin is indicated as adjunctive therapy to diet in adolescent patients (10-17 years old) with hefh where use of a combination product is appropriate:,? patients not appropriately controlled with a statin or ezetimibe alone. ? patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),apo-ezetimine/simvastatin is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine, quantity: 200 mg - tablet, dispersible - excipient ingredients: magnesium stearate; microcrystalline cellulose; mannitol; aspartame; povidone; croscarmellose sodium; colloidal anhydrous silica; crospovidone; flavour - torrent lamotrigine dispersible tablets are indicated for the treatment of: partial and generalised seizures in adults and children. there is extensive experience with torrent lamotrigine use initially as add-on therapy. torrent lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy in newly diagnosed paediatric patients is not recommended. (see actions, clinical trials.)

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine, quantity: 100 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; mannitol; magnesium stearate; aspartame; croscarmellose sodium; colloidal anhydrous silica; crospovidone; povidone; flavour - torrent lamotrigine dispersible tablets are indicated for the treatment of: partial and generalised seizures in adults and children. there is extensive experience with torrent lamotrigine use initially as add-on therapy. torrent lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy in newly diagnosed paediatric patients is not recommended. (see actions, clinical trials.)

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine, quantity: 50 mg - tablet, dispersible - excipient ingredients: croscarmellose sodium; povidone; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; aspartame; mannitol; magnesium stearate; flavour - torrent lamotrigine dispersible tablets are indicated for the treatment of: partial and generalised seizures in adults and children. there is extensive experience with torrent lamotrigine use initially as add-on therapy. torrent lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy in newly diagnosed paediatric patients is not recommended. (see actions, clinical trials.)

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine, quantity: 25 mg - tablet, dispersible - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica; mannitol; aspartame; crospovidone; microcrystalline cellulose; croscarmellose sodium; flavour - torrent lamotrigine dispersible tablets are indicated for the treatment of: partial and generalised seizures in adults and children. there is extensive experience with torrent lamotrigine use initially as add-on therapy. torrent lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy in newly diagnosed paediatric patients is not recommended. (see actions, clinical trials.)

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine -

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - lamotrigine -